Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00003014
Recruitment Status : Completed
First Posted : March 12, 2004
Last Update Posted : December 4, 2013
European Organisation for Research and Treatment of Cancer - EORTC
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether chemotherapy is more effective than radiation therapy for testicular cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin with that of radiation therapy in treating patients who have stage I testicular cancer.

Condition or disease Intervention/treatment Phase
Testicular Germ Cell Tumor Drug: carboplatin Radiation: radiation therapy Phase 3

Detailed Description:

OBJECTIVES: I. Compare relapse rates in patients with stage I testicular seminoma treated with adjuvant radiotherapy vs carboplatin. II. Compare quality of life of patients before and after treatment with these regimens. III. Compare the acute and intermediate (1-2 year) side effects of these regimens in these patients. IV. Determine the incidence of late side effects (such as bowel dysfunction) of treatment and second malignancies in these patients.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive a single dose of carboplatin IV. Arm II: Patients undergo radiotherapy once daily, 5 days a week. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.

PROJECTED ACCRUAL: Approximately 800 patients will be accrued for this study within 4 years.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Carboplatin in the Adjuvant Treatment of Stage I Seminoma: A Radomized Comparison of Single Agent Carboplatin With Radiotherapy in the Adjuvant Treatment of Stage I Seminoma of the Testis, Following Orchidectomy
Study Start Date : April 1998
Actual Study Completion Date : July 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Carboplatin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

DISEASE CHARACTERISTICS: Histologically confirmed stage I seminomatous germ cell tumor of the testis categorized as either "classical" or "anaplastic"

PATIENT CHARACTERISTICS: Age: 16 and over Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Creatinine less than 1.4 mg/dL Other: No concurrent or previously treated malignancy except successfully treated nonmelanoma skin cancer No medical condition or other factor that would preclude study

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: No more than 8 weeks since prior orchidectomy Prior inguino-pelvic or scrotal surgery allowed Must be treated with "dog-leg" field if randomized to radiotherapy If prior vasectomy, choice of fields is at the discretion of the clinician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00003014

  Hide Study Locations
Porto Alegre Hospital
Porto Alegre, Rio Grande do Sul, Brazil, 90035--003
Canada, Ontario
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada, N6A 4L6
Mount Sinai Hospital - Toronto
Toronto, Ontario, Canada, M5G 1X5
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Hopital Sainte Justine
Montreal, Quebec, Canada, H3T 1C5
Maria Hospital
Helsinki, Finland, FIN-0-0180
Antoni van Leeuwenhoekhuis
Amsterdam, Netherlands, 1066 CX
Norwegian Radium Hospital
Oslo, Norway, N-0310
South Africa
Groote Schuur Hospital, Cape Town
Cape Town, South Africa, 7925
United Kingdom
Royal United Hospital
Bath, England, United Kingdom, BA1 3NG
University of Birmingham
Birmingham, England, United Kingdom, B15 2TT
Children's Hospital - Birmingham UK
Birmingham, England, United Kingdom, B16 8ET
Bradford Hospitals NHS Trust
Bradford, England, United Kingdom, BD9 6RJ
Royal Sussex County Hospital
Brighton, England, United Kingdom, BN2 5BE
Bristol Royal Hospital for Sick Children
Bristol, England, United Kingdom, BS2 8BJ
Bristol Haematology and Oncology Centre
Bristol, England, United Kingdom, BS2 8ED
Addenbrooke's NHS Trust
Cambridge, England, United Kingdom, CB2 2QQ
Kent and Canterbury Hospital
Canterbury, England, United Kingdom, CT2 7NR
Walsgrave Hospital
Coventry, England, United Kingdom, CV2 2DX
Derbyshire Royal Infirmary
Derby, England, United Kingdom, DE1 2QY
Derbyshire Children's Hospital
Derby, England, United Kingdom, DE1 3BA
Royal Devon and Exeter Hospital
Exeter, England, United Kingdom, EX2 5DW
Gloucester Royal NHS Trust - Glouchester Royal Hospital
Gloucester, England, United Kingdom, GL1 3NN
Royal Surrey County Hospital
Guildford, England, United Kingdom, GU2 5XX
Royal Free Hospital
Hampstead, London, England, United Kingdom, NW3 2QG
Huddersfield Royal Infirmary
Huddersfield, West Yorks, England, United Kingdom, HD3 3EA
Cookridge Hospital
Leeds, England, United Kingdom, LS16 6QB
St. James's Hospital
Leeds, England, United Kingdom, LS9 7TF
University Hospitals of Leicester
Leicester, England, United Kingdom, LE1 5WW
Saint Bartholomew's Hospital
London, England, United Kingdom, EC1A 7BE
St. Bartholomew's Hospital
London, England, United Kingdom, EC1A 7BE
Guy's and St. Thomas' Hospitals Trust
London, England, United Kingdom, SE1 7EH
Westminster Hospital
London, England, United Kingdom, SW1P 2AP
University College Hospital
London, England, United Kingdom, WC1E 6AU
Middlesex Hospital- Meyerstein Institute
London, England, United Kingdom, WIT 3AA
Manchester Children's Hospitals (NHS Trust)
Manchester, England, United Kingdom, M27 SHA
Clatterbridge Centre for Oncology NHS Trust
Merseyside, England, United Kingdom, L63 4JY
South Tees Acute Hospitals NHS Trust
Middlesbrough, Cleveland, England, United Kingdom, TS4 3BW
Newcastle General Hospital
Newcastle Upon Tyne, England, United Kingdom, NE4 6BE
Newcastle Upon Tyne Hospitals NHS Trust - Freeman Hospital
Newcastle-Upon-Tyne, England, United Kingdom, NE7 7DN
Mount Vernon Hospital
Northwood, England, United Kingdom, HA6 2RN
Norfolk & Norwich Hospital
Norwich, England, United Kingdom, NR1 3SR
Oxford Radcliffe Hospital
Oxford, England, United Kingdom, 0X3 9DU
Portsmouth Hospitals NHS Trust
Portsmouth, England, United Kingdom, P03 6AD
Children's Hospital - Sheffield
Sheffield, England, United Kingdom, S10 2TH
Weston Park Hospital
Sheffield, England, United Kingdom, S1O 2SJ
Royal South Hants Hospital
Southampton, England, United Kingdom, SO14 0YG
Southampton General Hospital
Southampton, England, United Kingdom, SO16 6YD
Royal Marsden Hospital
Sutton, England, United Kingdom, SM2 5PT
Princess Royal Hospital
Telford, England, United Kingdom, TF6 6TF
Walsall Manor Hospital
Walsall, England, United Kingdom, WS2 9PS
Southend NHS Trust Hospital
Westcliff-On-Sea, England, United Kingdom
Royal Belfast Hospital for Sick Children
Belfast, Northern Ireland, United Kingdom, BT12 6BE
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom, AB25 2ZN
Ninewells Hospital and Medical School
Dundee, Scotland, United Kingdom, DD1 9SY
Western General Hospital
Edinburgh, Scotland, United Kingdom, EH4 9NQ
Royal Hospital for Sick Children
Edinburgh, Scotland, United Kingdom
Beatson Oncology Centre
Glasgow, Scotland, United Kingdom, G11 6NT
Royal Infirmary
Glasgow, Scotland, United Kingdom, G4 0SF
Ysbyty Gwynedd
Bangor, Wales, United Kingdom, LL57 2PW
Llandough Hospital
Penarth, Wales, United Kingdom, CF6 1XX
Royal Preston Hospital
Preston, United Kingdom, PR2 9HT
Sponsors and Collaborators
Medical Research Council
European Organisation for Research and Treatment of Cancer - EORTC
Study Chair: Hans Von Der Maase, MD Aarhus Universitetshospital - Aarhus Sygehus
Study Chair: R. T. Oliver, MD St. Bartholomew's Hospital

Publications of Results:
Oliver RT, Mason M, Von der Masse H, et al.: A randomised comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. [Abstract] J Clin Oncol 22 (Suppl 14): A-4517, 386, 2004.
Oliver RT, Mead GM, Fogarty PJ, et al.: Radiotherapy versus carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214). [Abstract] J Clin Oncol 26 (Suppl 15): A-1, 2008.

Other Publications: Identifier: NCT00003014     History of Changes
Other Study ID Numbers: CDR0000065594
First Posted: March 12, 2004    Key Record Dates
Last Update Posted: December 4, 2013
Last Verified: March 2011

Keywords provided by National Cancer Institute (NCI):
stage I malignant testicular germ cell tumor
testicular seminoma

Additional relevant MeSH terms:
Neoplasms, Germ Cell and Embryonal
Testicular Neoplasms
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Male
Urogenital Neoplasms
Genital Diseases, Male
Endocrine System Diseases
Testicular Diseases
Gonadal Disorders
Antineoplastic Agents